UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2388-2395

2013

Volltextzugriff (PDF)

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3810-3818

2012

Volltextzugriff (PDF)

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2413-2420

2013

Volltextzugriff (PDF)

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment

European journal of cancer (1990), 2016-03, Vol.56, p.101-106

2016

Volltextzugriff (PDF)

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)

European journal of cancer (1990), 2009-12, Vol.45 (18), p.3189-3197

2009

Volltextzugriff (PDF)

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2018-07, Vol.19 (7), p.916-929

2018

Volltextzugriff (PDF)

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status

Psychiatry and clinical neurosciences, 2008-10, Vol.62 (5), p.597-602

2008

Volltextzugriff (PDF)

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands

Melanoma research, 2021-06, Vol.31 (3), p.249-257

2021

Volltextzugriff (PDF)

Pimasertib‐associated ophthalmological adverse events

Acta ophthalmologica (Oxford, England), 2018-11, Vol.96 (7), p.712-718

2018

Volltextzugriff (PDF)

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

International journal of cancer, 2005-11, Vol.117 (4), p.596-604

2005

Volltextzugriff (PDF)

Thalidomide in solid tumours: the resurrection of an old drug

European journal of cancer (1990), 2004-11, Vol.40 (16), p.2377-2382

2004

Volltextzugriff (PDF)

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

Cancer Immunology, Immunotherapy, 2013-07, Vol.62 (7), p.1223-1233

2013

Volltextzugriff (PDF)

IL-12: a promising adjuvant for cancer vaccination

Cancer Immunology, Immunotherapy, 2003-03, Vol.52 (3), p.133-144

2003

Volltextzugriff (PDF)

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Clinical cancer research, 2003-01, Vol.9 (1), p.76-83

2003

Volltextzugriff (PDF)

Interferon-α in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated

Psychosomatics (Washington, D.C.), 2008-01, Vol.49 (1), p.56-63

2008

Volltextzugriff (PDF)

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

Amino acids, 2009-10, Vol.37 (4), p.703-708

2009

Volltextzugriff (PDF)

Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer

Clinical cancer research, 1999-12, Vol.5 (12), p.3983-3989

1999

Volltextzugriff (PDF)

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

Neuropsychobiology, 2007-01, Vol.55 (3-4), p.225-231

2007

Volltextzugriff (PDF)

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant

Cancer Immunology, Immunotherapy, 2005-01, Vol.54 (1), p.37-43

2005

Volltextzugriff (PDF)

Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients

Psychiatry research, 2003-07, Vol.119 (1), p.125-132

2003

Volltextzugriff (PDF)

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

British journal of haematology, 2001-02, Vol.112 (2), p.499-505

2001

Volltextzugriff (PDF)

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients

Progress in neuro-psychopharmacology & biological psychiatry, 2005, Vol.29 (1), p.109-114

2005

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Humans
(29)
Female
(22)
Middle Aged
(22)
Adult
(21)
Aged
(21)
Male
(21)
Oncology
(20)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Melanoma - Drug Therapy
(14)
Pharmacology. Drug Treatments
(12)
Skin Neoplasms - Drug Therapy
(11)
Interferon-Alpha - Therapeutic Use
(10)
Dose-Response Relationship, Drug
(8)
Tumors
(8)
Carcinoma, Renal Cell - Drug Therapy
(7)
Melanoma
(7)
Time Factors
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands

Pimasertib‐associated ophthalmological adverse events

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry

Thalidomide in solid tumours: the resurrection of an old drug

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

IL-12: a promising adjuvant for cancer vaccination

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Interferon-α in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant

Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients

Aktive Filter

Suchergebnisse filtern